ClinicalTrials.gg
RecruitingNCT07464613COSMOUpdated May 26, 2026

Social Cognition in Severe Alcohol Use Disorder

An interventional study of Analysis of social functioning and social cognition processes in Alcohol Use Disorder, sponsored by CHU de Reims. Recruiting at 1 site in France. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-26.

Sponsored by CHU de Reims · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 94 studies in Alcoholism with a site in France — 24 open to participants now, 25 under way, 1 of them phase 3. Alcoholism · France.

Planned enrollment
48th of 58
60 · median 153
Started
2026
with 7 others
No phase
42 of 94
15 open now
Primary completion
2028-11
later than 21 of 24 live
Registered
90th of 94
by date
Lead sponsor
4 of 94
CHU de Reims

Among the 94 studies in Alcoholism with a site in France, this one is the 48th largest by planned enrollment of the 58 interventional ones that give a count, is one of 8 that started in 2026, is one of 42 with no phase, reaches primary completion later than 21 of the 24 other live ones, and was the 90th registered.

Alcoholism

1,679 studies on the registry are indexed under Alcoholism; 333 are open to participants now.

Browse Alcoholism studies →

Open to participants now

24 of the 94 studies in Alcoholism with a site in France are open now. Recruiting first, the newest first:

18 more — sign in →

All 24 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 238 Alcoholism studies recruiting now, 85 (36%) set no upper age limit and 131 (55%) stop at 75 or younger; 9 take children under 18; 64 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 94 studies in Alcoholism with a site in France, or all of them as a file.
02

Study summary

With 41,000 deaths per year, alcohol consumption is the second leading cause of preventable mortality in France. Nearly 3.4% of adults engage in excessive and chronic alcohol use, meeting criteria for Severe Alcohol Use Disorder (SAUD).

SAUD is associated with cerebral and cognitive alterations, including deficits in social cognition. These deficits manifest as difficulties in perceiving and interpreting social cues during interactions and encompass, in particular, the recognition of emotional facial expressions and the accurate attribution of others' beliefs, emotions, and intentions (i.e., theory of mind). Such alterations contribute to interpersonal difficulties and psychological distress and are recognized as risk factors for the development and maintenance of SAUD.

To date, social cognition has primarily been explored through behavioral tests, providing a description of deficits without examining their neuro-structural correlates. Moreover, no neuroscientific study has investigated the impact of sex and concomitant tobacco use on social cognition and associated brain structures in SAUD, although these factors are known to influence both social cognitive abilities and cerebral organization in this disorder. Finally, the everyday consequences of these alterations on social functioning and the trajectory of alcohol consumption remain poorly explored.

In this context, the present project aims, first, to explore the neuro-structural correlates of social cognition deficits in SAUD using psychometric assessments (i.e., emotion recognition, theory of mind) combined with magnetic resonance imaging (MRI). The impact of sex and tobacco use will be accounted for by including these variables as covariates in statistical analyses. Second, the project seeks to assess the daily-life impact of social cognition deficits on the social functioning of individuals with SAUD (i.e., quantity and quality of social interactions) and on the evolution of alcohol use behaviors six months after hospitalization (i.e., risk of relapse).

The study will include two participant groups: individuals with SAUD and age-, sex-, and education-matched control participants.

The expected results will refine our understanding of social cognition alterations in SAUD, thereby contributing to the improvement of current neuroscientific models. These advances will pave the way for the identification of potential targets for prevention programs and therapeutic interventions.

Read the detailed description

Nearly 3.4% of adults engage in excessive and chronic alcohol use, meeting criteria for Severe Alcohol Use Disorder (SAUD). SAUD is associated with cerebral and cognitive alterations, including deficits in social cognition. These deficits manifest as difficulties in perceiving and interpreting social cues during interactions and encompass, in particular, the recognition of emotional facial expressions and the accurate attribution of others' beliefs, emotions, and intentions (i.e., theory of mind). Such alterations contribute to interpersonal difficulties and psychological distress and are recognized as risk factors for the development and maintenance of SAUD.

To date, social cognition has primarily been explored through behavioral tests, providing a description of deficits without examining their neuro-structural correlates. Moreover, no neuroscientific study has investigated the impact of sex and concomitant tobacco use on social cognition and associated brain structures in SAUD, although these factors are known to influence both social cognitive abilities and brain organization in this disorder. Finally, the everyday consequences of these alterations on social functioning and the trajectory of alcohol consumption remain poorly explored.

In this context, the present project aims, first, to explore the neuro-structural correlates of social cognition deficits in SAUD using psychometric assessments (i.e., emotion recognition, theory of mind) combined with magnetic resonance imaging (MRI). The impact of sex and tobacco use will be accounted for by including these variables as covariates in statistical analyses. Second, the project seeks to assess the daily-life impact of social cognition deficits on the social functioning of individuals with SAUD (i.e., quantity and quality of social interactions) and on the evolution of alcohol use behaviors six months after hospitalization (i.e., risk of relapse).

The study will include two participant groups: individuals with SAUD and age-, sex-, and education-matched control participants. The expected results will refine our understanding of social cognition alterations in SAUD, thereby contributing to the improvement of current neuroscientific models. These advances will pave the way for the identification of potential targets for prevention programs and therapeutic interventions.

Detailed Description

  1. State of the Art Severe Alcohol Use Disorder (SAUD) is associated with structural and functional brain alterations as well as cognitive impairments affecting memory and executive functions. Recent research also highlights deficits in social cognition, including emotion recognition and theory of mind.

    However, the neural correlates of these deficits remain poorly understood. Most neuroimaging studies in SAUD have focused on functional MRI tasks involving implicit emotional processing, whereas clinical neuropsychology typically relies on explicit behavioral assessments. Consequently, the structural brain correlates (gray and white matter) of social cognition deficits in SAUD remain largely unexplored.

    Social cognition impairments may contribute to difficulties in daily social functioning and could increase relapse risk. Ecological Momentary Assessment (EMA), combined with passive smartphone data, enables real-time assessment of social interactions in naturalistic settings and may provide a more accurate measure of daily social functioning than retrospective reports.

  2. Aims of this protocol

    Primary Objective:

    - To investigate structural brain correlates (gray matter and white matter) of social cognition deficits (emotion recognition and theory of mind) in patients with SAUD.

    Secondary Objectives:

    • To examine the influence of sex and tobacco use on cognitive and brain alterations related to social cognition
    • To assess the relationship between social cognition deficits and daily social functioning using EMA and passive smartphone data
    • To evaluate whether cognitive and brain alterations in social cognition predict relapse risk six months after detoxification.
  3. Hypotheses Social Cognition and Brain Alterations H1a: SAUD patients will show reduced gray matter volume and white matter integrity in brain regions involved in socio-emotional processing.

    H1b: Structural alterations will be associated with performance on social cognition tasks.

    H1c: Sex and tobacco use may modulate these associations. Social Cognition and Daily Functioning H2: Cognitive and brain deficits will predict poorer daily social functioning, assessed through self-reported interactions and passive smartphone data.

    Social Cognition and Relapse H3: Cognitive and brain deficits will predict relapse risk (alcohol consumption, craving, anxiety, depression) six months after detoxification.

  4. Recruitment of participants

    Two groups will be recruited:

    SAUD patients (n = 30): Individuals hospitalized for alcohol withdrawal, abstinent for at least two weeks, without other substance use disorders (except tobacco use disorder and occasional cannabis consumption) or severe psychiatric/neurological illness.

    Healthy controls (n = 30): Individuals without substance use disorders or severe psychiatric/neurological illness, matched for age and socioeconomic status.

  5. Levels of investigation Clinical Assessment: A physician specialized in addiction medicine will collect sociodemographic and clinical data, including alcohol and drug use, psychiatric symptoms, impulsivity, and socio-emotional functioning (e.g., empathy, alexithymia, emotion regulation).

    Neuropsychological Assessment: Participants will complete tests assessing general cognitive functioning, executive functions (inhibition, mental flexibility), and social cognition (facial emotion recognition and theory of mind).

    MRI: MRI acquisition will include structural T1-weighted imaging, diffusion tensor imaging (DTI), and functional MRI during the viewing of two short movie clips.

    Ecological Momentary Assessment (EMA): For 14 days following the MRI session, participants will complete a daily smartphone questionnaire assessing social interactions. Passive smartphone data (e.g., call frequency, time on communication apps, step count) will also be collected to estimate social activity.

  6. Study timeline

Assessments will occur at multiple time points:

  1. Clinical evaluation
  2. Neuropsychological assessment
  3. MRI acquisition
  4. EMA and passive smartphone data collection (14 days)
  5. Six-month follow-up assessing relapse outcomes in SAUD patients 7/ Statistical analyses Group differences will be tested using mean comparisons, ANOVA, and generalized linear models. Associations between neuropsychological performance and neuroimaging measures will be examined using correlation analyses and regression models.

Structural MRI analyses will assess gray matter volume, cortical thickness, and cortical surface area across the whole brain and within social cognition-related regions of interest. White matter integrity will be evaluated using diffusion measures (fractional anisotropy, mean diffusivity) and tractography.

Regression analyses will identify predictors of social cognition deficits, daily social functioning (EMA and passive data), and relapse outcomes.

03

Conditions studied

  • Alcohol Use Disorder

Keywords

  • Alcohol use disorder
  • MRI exam
  • social cognition
  • social functioning
  • neuropsychology
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

  1. AUD patients

    Inclusion criteria:

    • Patients between 18 and 65 years old, men or women, right-handed, following AUD treatment as inpatients or outpatients and currently abstinent
    • Having a diagnosis of severe alcohol use disorder according to criteria
    • Native French speakers
    • Patients enrolled in the national healthcare insurance program
    • Patients consenting to participate in the study

    Exclusion criteria:

    • A diagnosis of schizophrenia, of any other chronic psychotic state, or of bipolar disorder according to DSM-5 criteria
    • The presence of a current depressive episode as defined by DSM-5 criteria
    • The presence of another moderate or severe substance use disorder according to DSM-5 criteria, except for tobacco and cannabis if alcohol is the primary substance consumed and the criteria for cannabis dependence are not met
    • The presence of a neurodevelopmental disorder
    • The presence of any or unstable pathology: organic pathology affecting the central nervous system or disease likely to interfere with assessments, including the neurological complications of alcoholism
    • Having any uncorrected auditory or visual deficits
    • to the use of MRI
    • Individuals particularly protected by the law
    • No smartphone with Apple or Android operating system
  2. Healthy control participants:

Inclusion criteria:

  • Participants between 18 and 65 years old, men or women, right-handed
  • Native French speakers
  • Participants enrolled in the national healthcare insurance program
  • Participants consenting to participate in the study

Exclusion criteria:

  • A diagnosis of schizophrenia, of any other chronic psychotic state, or of bipolar disorder according to DSM-5 criteria
  • The presence of a current depressive episode as defined by DSM-5 criteria
  • The presence of substance use disorder as defined by DSM-5 diagnostic criteria, except for tobacco dependence
  • Having any first-degree relative with alcohol use disorder according to DSM-5 diagnostic criteria
  • The presence of a neurodevelopmental disorder
  • The presence of any clinically significant or unstable pathology: organic pathology affecting the central nervous system
  • Having any uncorrected auditory or visual deficits
  • Contraindication to the use of MRI
  • Individuals particularly protected by the law
  • No smartphone with Apple or Android operating system
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    AUD patients

    Alcohol Use Disorder patients

    Behavioral: Analysis of social functioning and social cognition processes

  • Experimental
    AUD controls

    Healthy control participants matched to group 1

    Behavioral: Analysis of social functioning and social cognition processes

Interventions

  • BehavioralAnalysis of social functioning and social cognition processes

    Investigation of functioning and social cognition processes using a comprehensive, neuropsychological assessment and MRI exam. * Evaluation of addictive, psychiatric and neurological comorbidities. * Neuropsychological assessment establishing the participants cognitive profiles of executive functions and of social cognition * Collection of smartphone-based data that is descriptive of participants daily social functioning * MRI exam identifying participants neuroanatomical and neurofunctional correlates of social cognition processes

06

What researchers measure

Primary outcomes

  1. MRI exam: brain structures

    Evaluated through a high-resolution 3D anatomical image, diffusion tensor images and a functional MRI sequence (passive visualization of two short movie clips). Examination of brain structures to identify the neuroanatomical and neurofunctional correlates of social cognition processes in the Alcohol Use Disorder patients.

    Time frame: Day 3

  2. Social cognition: facial emotion recognition

    Evaluated through a test of facial emotion recognition (TREF). The participant is shown 54 photographs depicting 6 different emotions of variable intensity (joy, anger, sadness, disgust, contempt, fear) for which he must choose the corresponding emotion label. Are measured participant's response times, the number of correct responses (score out of 54) and type of errors. (Gaudelus, B., Virgile, J., Peyroux, E., b, Leleu, A., c, Baudouin J.Y., Franck N. (2015). Mesure du déficit de reconnaissance des émotions faciales dans la schizophrénie. Étude préliminaire du test de reconnaissance des émotions faciales (TREF). L'Encéphale 41(3), 251-259.)

    Time frame: Day 2

  3. Social cognition: cognitive and affective theory of mind

    Evaluated through The Movie of Assessment for Social Cognition (MASC). The participant is shown a movie of approximately 15 minutes displaying people interacting with each other. From time to time, the movie is stopped, and the participant must answer different questions relating to the thoughts and feelings of the characters. Are measured the number of correct responses out of 45. (Dziobek I, Fleck S, Kalbe E, Rogers K, Hassenstab J, Brand M, Kessler J, Woike JK, Wolf OT, Convit A.J (2006). Journal of Autism and Developmental Disorders 36(5), 623-36.)

    Time frame: Day 2

  4. Everyday social functioning: EMA and passive smartphone data

    Daily social functioning will be assessed using Ecological Momentary Assessment (EMA) via the Behapp application (University of Groningen). Behapp will send a daily questionnaire to the participant's smartphone at the end of the day for 14 consecutive days, assessing the quantity and quality of social interactions through 20 items. The Behapp app collects passive mobile data providing a more comprehensive evaluation of social functioning : Number and duration of incoming and outgoing phone calls (only metadata are collected), time spent on social media applications (only aggregated data are collected), number of unique locations visited (without GPS coordinates or exact addresses), screen states and movement patterns (e.g., step counts). (Jagesar, R. R., at al (2021). Digital phenotyping and the COVID-19 pandemic: capturing behavioral change in patients with psychiatric disorders. European Neuropsychopharmacology, 42, 115-120.)

    Time frame: During 14 days

Secondary outcomes

  1. Executive functions: mental flexibility performances and processing speed

    Evaluated through the Trail Making Test (TMT parts A and B). In part A the participant must connect as quick as possible all the numbers on a sheet of paper in ascending order (1-25). In part B the participant is asked to connect all the numbers in ascending order (1-13) and all the letters according to their alphabetical order (A-L) whilst alternating between numbers and letters and without lifting the pencil. For both parts is reported the time necessary for task completion in seconds. (Reitan RM, Wolfson D (1985) The Halstead-Reitan Neuropsychological Test Battery. Neuropsychology Press, Tucson, AZ.)

    Time frame: Day 2

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Nov 2028, 30 months after the start.

Of 472 non-industry interventional studies with no phase under Alcoholism, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 54. This study's planned 30 months is below that.

Counting every sponsor, half of 495 studies reached it within 33 months; a quarter within 17 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2026
First posted
Mar 11, 2026
StartActual
May 11, 2026
Primary completionEst.
Nov 11, 2028
CompletionEst.
Dec 2028
Last update
May 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07464613
Lead sponsor
CHU de Reims
Collaborators
Université de Reims Champagne-Ardenne, Public Mental Health Institution of the Marne
Responsible party
Sponsor
First posted
Mar 11, 2026
Start date
May 11, 2026
Primary completion
Nov 11, 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
May 26, 2026

Study contacts

Franca Schmid
Contact
franca.schmid1@univ-reims.fr
03 26 61 19 30 ext. 0033
Farid Benzerouk
Contact
benzeroukf@epsm-marne.fr
03 26 61 19 30 ext. 0033

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion